Skip to content

Addressing HIV risk behaviour in South Africa: Yes, HIV testing in treatment centres in important, but far more is needed

Addressing HIV risk behaviour in South Africa: Yes, HIV testing in treatment centres in important, but far more is needed

By continuing to browse this site you agree to us using cookies as described in About Cookies Previous article in issue: HIV testing and sero-prevalence among methamphetamine users seeking substance abuse treatment in Cape Town Next article in issue: Novel psychoactive substance use by US adolescents: Characteristics associated with use of synthetic cannabinoids and synthetic cathinones…
See all stories on this topic

The policy and practices of New South Wales drug treatment providers in responding to the possession of illicit substances on premises

Conclusions.The policy and practice in these settings vary greatly, with many services reporting no documented policy to guide staff. The findings suggest the need to develop organisational policy to support service providers in responding to possession of illicit substances on premises. [Stirling R, Day C. The policy and practices of New South Wales drug treatment providers in responding to the p
See all stories on this topic

A randomised trial of a computer‐delivered screening and brief intervention for postpartum alcohol use

ConclusionsThis pilot trial failed to support a single‐session e‐SBI for alcohol use among postpartum women, although findings at the 3‐month time point suggested that greater power might confirm transient effects of the e‐SBI. As efficacy is likely to vary with e‐SBI content and approach, future research should leverage technology’s reproducibility and modularity to isolate key componen
See all stories on this topic

FDA announces enhanced warnings for immediate-release opioid pain medications related to risks of misuse, abuse, addiction, overdose and death

March 22, 2016 — In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose a
See all stories on this topic

FDA requires boxed warnings for short-acting opioids

The Food and Drug Administration will require boxed warnings on the risks of abuse, misuse, addiction, overdose, and death for all immediate-release opioids. The decision is part of the latest wave of efforts by federal officials to combat the ballooning opioid epidemic. It comes a week after the Centers for Disease Control and Prevention issued guidelines recommending nonopioid analgesia for non
See all stories on this topic

Published inAddiction

Be First to Comment

Leave a Reply